Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dean Moscovic

Internal Medicine Clarkston, MI Doctor of Osteopathy

NPI 1952309718 CMS profile 223853

5701 Bow Pointe Drive, Suite 100, Clarkston, MI 48346

Open in the dashboard

General payments

$4,877

395 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$137,756 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Dean Moscovic of Clarkston, MI is reported in the CMS Open Payments database as having received $4,877 across 395 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $137,756 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,074 79
2024 General $686 48
2023 General $677 54
2022 General $886 67
2021 General $628 45
2020 General $204 14
2019 General $721 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dean Moscovic
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dean Moscovic were reported at $1,074. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dean Moscovic Internal Medicine median Middle half National median
2019 $721 $159 $48–$570 $163
2020 $204 $119 $33–$402 $114
2021 $628 $135 $37–$521 $132
2022 $886 $141 $42–$496 $149
2023 $677 $149 $45–$519 $160
2024 $686 $154 $47–$537 $164
2025 $1,074 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,147 99 payments
  2. AbbVie, Inc. $859 67 payments
  3. Pfizer Inc. $820 67 payments
  4. Lilly USA, LLC $466 48 payments
  5. Amgen Inc. $352 28 payments
  6. Merck Sharp & Dohme Corporation $214 24 payments
  7. AstraZeneca Pharmaceuticals LP $171 8 payments
  8. GlaxoSmithKline, LLC. $156 14 payments
  9. Novartis Pharmaceuticals Corporation $149 9 payments
  10. Teva Pharmaceuticals USA, Inc. $69 4 payments
  11. Other $475 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,838 392 payments
  2. Education $39 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $893 78 payments
  2. RYBELSUS $884 77 payments
  3. UBRELVY $619 42 payments
  4. NURTEC ODT $577 39 payments
  5. ZAVZPRET $419 26 payments
  6. QULIPTA $265 15 payments
  7. MOUNJARO $221 18 payments
  8. TRULICITY $214 21 payments
  9. EVENITY $200 17 payments
  10. Prolia $200 17 payments
  11. Other $3,749 353 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 222 drugs

Part D claims

16,305

Median for Pediatric Medicine: 38

Drug cost

$1,756,038

Median for Pediatric Medicine: $2,769

Branded share of claims

27.4%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 179 $261,405
Ozempic Semaglutide Brand 159 $226,625
Eliquis Apixaban Brand 180 $168,315
Jardiance Empagliflozin Brand 122 $144,346
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 108 $95,563
Xeljanz Xr Tofacitinib Citrate Brand 16 $85,510
Enbrel Etanercept Brand 11 $78,558
Januvia Sitagliptin Phosphate Brand 50 $50,994
Xarelto Rivaroxaban Brand 34 $43,751
Trulicity Dulaglutide Brand 16 $29,386

The 10 drugs with the highest cost, of 222 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$186,649

Of which drugs: $17,471

Medicare patients

554

Average age 72

Services billed

4,441

326 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 53%
Ischemic heart disease 31%
Diabetes 26%
Depression 21%
Heart failure 19%
Chronic kidney disease 19%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 34 34 $9,894
Vaccine for influenza for injection into muscle 90662 Office 62 62 $5,023
Sarscv2 vac 30mcg trs-suc im 91320 Office 15 15 $2,267
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 28 $25
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 31 218 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $103
$103 — —
Ozempic
  • Novo Nordisk Inc $103
$103 159 —
UBRELVY
  • AbbVie, Inc. $84
$84 — —
NURTEC ODT
  • PFIZER INC. $73
$73 11 —
ZAVZPRET
  • PFIZER INC. $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record